IMAB, a clinical-stage biotechnology company, saw its stock price rise by 6.37%, reaching $1.09 per share with a trading volume of 274,740 shares. The stock's turnover rate was 0.34%, with a price fluctuation of 6.86%. Recent financial reports show zero revenue, a net loss of $17.82 million, and an earnings per share of -$0.30. The price-to-earnings ratio stands at -1.11.
All three analysts covering IMAB have issued a buy recommendation, with no hold or sell suggestions. Within the biotechnology sector, the overall increase was 0.40%. Notably, Cyclerion Therapeutics, Inc. and Exicure, Inc. showed significant gains, while Cyclerion Therapeutics, Inc. had a high turnover rate of 3732.05%.
